learn GT20029
research compound made to degrade androgen receptors in scalp
Search
forLearn
5 / 16 resultslearn Fluridil
a topical anti-androgen with less systemic involvement
learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn Bicalutamide
a nonsteroidal anti-androgen, most commonly used orally for women
learn Cyproterone
a synthetic anti-androgen and weak progestogen that inhibits DHT binding to androgen receptor
Research
5 / 1000+ resultsresearch Novel Androgen Receptor Degrader for Androgenetic Alopecia (AGA) Application
A new treatment for hair loss shows promise with fewer side effects.
research 52243 AH-001: An Emerging Androgen Receptor Degrader Showing Therapeutic Potential in Addressing Androgenetic Alopecia
AH-001 could be a safer and more effective treatment for hair loss.
research Androgen Receptor Modulators: A Review of Recent Patents and Reports (2012-2018)
New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.
research The Progress of Common Treatments and Research for Androgenetic Alopecia
Androgen receptor degrader drugs may be a promising future treatment for hair loss.
research Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
Community Join
5 / 1000+ resultscommunity Androgen degraders for hair loss
The conversation discusses androgen receptor degraders for hair loss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.
community A concern regarding the upcoming androgen degrader drug GT20029
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
community How much faith do you have in Kintor?
KX-826 is a potential hair loss treatment, with users discussing its effectiveness compared to finasteride and concerns about its trial results. Some users express skepticism about new treatments, while others discuss the potential of androgen receptor degraders and the need to manage drug resistance.
community Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
community Looks like Kintor finished enrollment and dosing of phase 1 for gt20029 in China.
The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.